AI-generated research brief — verify at source
Dapirolizumab Pegol Achieves Significantly Higher BICLA Response Than Placebo in Active SLE
In a phase 3 randomised controlled trial, dapirolizumab pegol produced a BICLA response at week 48 in 50% of patients with active systemic lupus erythematosus, compared with 35% in the placebo group — a statistically significant absolute difference of 14.6 percentage points (95% CI 3.3–25.8; p=0.011). The result confirms that CD40 ligand inhibition represents a viable and mechanistically distinct treatment approach for patients with moderate-to-severe SLE inadequately controlled by standard care.
What Was Studied
The trial investigated whether adding dapirolizumab pegol — a novel pegylated inhibitor of CD40 ligand (CD40L), a co-stimulatory molecule central to adaptive immune activation — to standard-of-care therapy could meaningfully reduce disease activity in patients with active SLE. The primary outcome was the proportion of patients achieving a BICLA (British Isles Lupus Assessment Group-based Composite Lupus Assessment) response at week 48, a validated composite endpoint reflecting sustained improvement across multiple disease domains.
How It Was Studied
PHOENYCS GO was a 48-week, randomised, double-blind, placebo-controlled phase 3 trial conducted across 177 centres — including hospitals, private practices, and dedicated trial sites — in 25 countries. Eligible patients were aged 16 years or older with moderate-to-severe, active SLE that persisted despite standard-of-care medication. A total of 321 patients were enrolled and randomly assigned in a 2:1 ratio to receive intravenous dapirolizumab pegol 24 mg/kg every four weeks (n=213) or matched placebo every four weeks (n=108), both administered on top of ongoing standard therapy. Patients, investigators, and trial funders were all blinded to treatment allocation. After exclusion of six patients due to Good Clinical Practice non-compliance at one site, the modified intention-to-treat population for efficacy analyses comprised 315 patients.
What Was Observed
- Primary endpoint met: Half of patients in the dapirolizumab pegol group (50%; 103/208) achieved a BICLA response at week 48, compared with 35% (37/107) in the placebo group — an absolute difference of 14.6 percentage points that was statistically significant (95% CI 3.3–25.8; p=0.011). This indicates that roughly one in seven additional patients responded to active treatment beyond what was seen with placebo.
- Overall adverse event burden was manageable: Treatment-emergent adverse events occurred more frequently in the dapirolizumab pegol arm (83%; 176/213) than in the placebo arm (75%; 81/108), though serious treatment-emergent adverse events were numerically lower with the active drug (10%; 21/213) compared with placebo (15%; 16/108).
- Infection and infusion-related signals were present but low in frequency: Serious infections occurred in 4% (8/213) of dapirolizumab pegol recipients versus 6% (6/108) of placebo recipients. Infusion-related hypersensitivity reactions were recorded in 3% (6/213) of patients receiving the active treatment.
- Rare but serious individual events occurred in the active treatment group: One patient in the dapirolizumab pegol arm experienced a thromboembolic event (myocardial infarction), and one separate patient in the same arm died from gangrene-related sepsis. No corresponding events were reported in the placebo group.
Why This Matters
This is a phase 3 trial demonstrating that inhibition of the CD40–CD40L co-stimulatory pathway can produce statistically significant and clinically meaningful reductions in SLE disease activity in patients who remain inadequately controlled on standard therapy. The mechanism of action targeted here is distinct from currently available biologic pathways used in SLE, suggesting that dapirolizumab pegol could eventually offer a new treatment option for a patient population with substantial unmet need. The authors conclude that the findings support continued investigation of this agent in SLE.
How to Read This Result
This large, multi-centre, double-blind phase 3 trial provides high-quality evidence supporting the efficacy of dapirolizumab pegol over 48 weeks, though the relatively modest absolute effect size (14.6 percentage points) and the trial’s single-year duration mean that longer-term efficacy maintenance and rare safety signals — including thromboembolic events — will require evaluation in subsequent studies before the full benefit-risk profile can be fully characterised.
Limitations
Six patients were excluded from efficacy analyses after one participating site was found to have violated Good Clinical Practice guidelines, introducing a minor element of uncertainty regarding the completeness and representativeness of the analysed population. Beyond this, the abstract does not explicitly enumerate additional study limitations, and the 48-week observation window may be insufficient to detect late-emerging safety events or to determine whether clinical responses are durable over the longer term.